In a phase II trial, the FGF21 analog PEGylated pegbelfermin (PGBF), given subcutaneously for 16 weeks, decreased hepatic lipid accumulation in NAFLD patients. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.